

Table S2 Treatment details in included trials.

Study	Treatments	
GEICAM	EC-D	Epirubicin 90 mg/m <sup>2</sup> plus cyclophosphamide 600 mg/m <sup>2</sup> for 4 cycles; docetaxel 100 mg/m <sup>2</sup> for 4 cycles
	EC→DCb	Epirubicin 90 mg/m <sup>2</sup> plus cyclophosphamide 600mg/m <sup>2</sup> for 4 cycles; docetaxel 75mg/m <sup>2</sup> plus carboplatin AUC 6 for 4 cycles
UMIN000003355	P→CEF	Four cycles of weekly paclitaxel (80 mg/m <sup>2</sup> , day 1, 8, 15) followed by four cycles of CEF (cyclophosphamide 500/epirubicin 100/5-fluorouracil 500 mg/ m <sup>2</sup> )
	PCb→CEF	Four 3-week cycles of carboplatin AUC 5 and weekly paclitaxel (80 mg/ m <sup>2</sup> , day 1, 8, 15) followed by four cycles of CEF (cyclophosphamide 500/epirubicin 100/5-fluorouracil 500 mg/ m <sup>2</sup> )
GeparSixto	P+A+Beva	18 weeks with paclitaxel (80 mg/ m <sup>2</sup> weekly), non-pegylated liposomal doxorubicin (20 mg/ m <sup>2</sup> weekly), and bevacizumab (15 mg/kg intravenously every 3 weeks for 6 cycles)
	P+A+Beva+Cb	18 weeks with paclitaxel (80 mg/ m <sup>2</sup> weekly), non-pegylated liposomal doxorubicin (20 mg/ m <sup>2</sup> weekly), carboplatin (AUC 1.5 weekly), and bevacizumab (15 mg/kg intravenously every 3 weeks for 6 cycles)
Mexico	P→AC	Weekly paclitaxel 80 mg/ m <sup>2</sup> by 12, followed to 5FU, doxorubicin and cyclophosphamide 500/50/500 mg/ m <sup>2</sup> every 3 weeks times 4
	PCis→AC	Cisplatin 30 mg/ m <sup>2</sup> plus weekly paclitaxel 80 mg/ m <sup>2</sup> by 12 cycles, followed to cisplatin 75 mg/ m <sup>2</sup> plus doxorubicin 50 mg/ m <sup>2</sup> every 3 weeks for 4 cycles
CALGB 40603	P→AC	paclitaxel 80 mg/ m <sup>2</sup> once per week for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks for four cycles
	P+Bev→AC	paclitaxel 80 mg/ m <sup>2</sup> once per week for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks for four cycles, bevacizumab 10 mg/kg once every 2 weeks for nine cycles.
	P+Cb→AC	paclitaxel 80 mg/ m <sup>2</sup> once per week for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks for four cycles, concurrent carboplatin AUC 6 once every 3 weeks for four cycles
	P+Cb+Bev→AC	paclitaxel 80 mg/ m <sup>2</sup> once per week for 12 weeks, followed by doxorubicin plus cyclophosphamide once every 2 weeks for four cycles, concurrent carboplatin AUC 6 once every 3 weeks for four cycles, bevacizumab 10 mg/kg once every 2 weeks for nine cycles.
GeparSepto	P→AC	12 weeks paclitaxel 90 mg/ m <sup>2</sup> (after study amendment, 125 mg/ m <sup>2</sup> ) on days 1, 8, and 15 for four 3-week cycles, epirubicin 90 mg/m <sup>2</sup> plus cyclophosphamide 600 mg/m <sup>2</sup> on day 1 for four 3-week cycles

	nabP→AC	12 weeks nab-paclitaxel 150 mg/m <sup>2</sup> (after study amendment, 125 mg/m <sup>2</sup> ) on days 1, 8, and 15 for four 3-week cycles, epirubicin 90 mg/m <sup>2</sup> plus cyclophosphamide 600 mg/m <sup>2</sup> on day 1 for four 3-week cycles
I-SPY2	P-AC	weekly paclitaxel 80 mg/ m <sup>2</sup> for 12 doses, doxorubicin (60 mg/ m <sup>2</sup> ) and cyclophosphamide (600 mg/ m <sup>2</sup> ) every 2 to 3 weeks for four doses
	P+Cb+Veli→AC	weekly paclitaxel 80 mg/ m <sup>2</sup> for 12 doses, doxorubicin (60 mg/ m <sup>2</sup> ), veliparib 50 mg by mouth twice daily for 12 weeks and carboplatin on weeks 1, 4, 7, and 10, concurrent with weekly paclitaxel; cyclophosphamide (600 mg/ m <sup>2</sup> ) every 2 to 3 weeks for four doses
Zhang et al.	PCb	paclitaxel (175 mg/ m <sup>2</sup> , day1) plus carboplatin (AUC 5, day2), every three weeks for 4-6 cycles
	PE	epirubicin (75mg/ m <sup>2</sup> , day1) plus paclitaxel (175 mg/ m <sup>2</sup> , day2) , every three weeks for 4-6 cycles
WSG-ADAPT-TN	nabP+Cb	nab-paclitaxel 125 mg/ m <sup>2</sup> , carboplatin AUC2 day 1,8 q3w
	nabP+Gem	nab-paclitaxel 125 mg/ m <sup>2</sup> , gemcitabine 1000 mg/ m <sup>2</sup> d1,8 three times weekly (q3w)
BrightNess	P→AC	paclitaxel (80 mg/ m <sup>2</sup> weekly for 12 doses), doxorubicin and cyclophosphamide every 2–3 weeks for four cycles
	P+Cb→AC	paclitaxel (80 mg/ m <sup>2</sup> weekly for 12 doses) plus carboplatin (AUC 6 every 3 weeks, for four cycles), doxorubicin and cyclophosphamide every 2–3 weeks for four cycles
	P+Cb+Veli→AC	paclitaxel (80 mg/ m <sup>2</sup> weekly for 12 doses) plus carboplatin (AUC 6 every 3 weeks, for four cycles) plus veliparib (50 mg orally, twice a day), doxorubicin and cyclophosphamide every 2–3 weeks for four cycles
ETNA	P→AC	paclitaxel 90 mg/ m <sup>2</sup> on weeks 1, 2, and 3, followed by a 1-week rest, for 4 cycles: 4 cycles of an anthracycline regimen per the investigator's choice
	nabP→AC	nab-paclitaxel group received 125mg/ m <sup>2</sup> on weeks 1, 2, and 3, followed by a 1-week rest, for 4 cycles; 4 cycles of an anthracycline regimen per the investigator's choice.
GeparNeuvo	nabP→AC	Nab-paclitaxel 125 mg/ m <sup>2</sup> weekly for 12 weeks, EC every 2 weeks for 4 cycles
	nabP+Durv→AC+Durv	Nab-paclitaxel 125 mg/ m <sup>2</sup> weekly for 12 weeks, EC every 2 weeks for 4 cycles; durvalumab (0.75g) 2 weeks before start of chemotherapy, then 1.5 g every 3 weeks with chemotherapy for 6 cycles.
GeparOLA	P+Olap→AC	12 cycles of paclitaxel weekly 80mg/ m <sup>2</sup> plus olaparib 100mg twice daily; epirubicin/cyclophosphamide 90/600 mg/ m <sup>2</sup> q2w or q3w
	P+Cb→AC	12 cycles of paclitaxel weekly 80mg/ m <sup>2</sup> plus carboplatin AUC 2;

		Epirubicin/Cyclophosphamide 90/600 mg/m <sup>2</sup> q2w or q3w
NeoTRIP	nabP+Cb+Ate	Carboplatin (AUC2) + nab-paclitaxel (125 mg/ m <sup>2</sup> ) weekly for 2 weeks every 3; 8 cycles; Atezolizumab (1200mg) day 1 every 3 weeks for 8 cycles
	nabP+Cb	Carboplatin (AUC2), nab-paclitaxel (125 mg/ m <sup>2</sup> ) weekly for 2 weeks every 3; 8 cycles
GeparOcto	E→P→C	18 weeks of epirubicin (150 mg/ m <sup>2</sup> ) followed by paclitaxel (225 mg/ m <sup>2</sup> ) followed by cyclophosphamide (2000 mg/ m <sup>2</sup> ), each q2w for 3 cycles
	PMCB	weekly paclitaxel (80 mg/ m <sup>2</sup> ) plus non-pegylated liposomal doxorubicin (20 mg/ m <sup>2</sup> ) plus carboplatin (AUC 1.5)
NeoStop	PCb→AC	paclitaxel 80 mg/ m <sup>2</sup> weekly for 12 cycles; carboplatin (AUC 6) every 3 weeks for 4 cycles, followed by doxorubicin 60 mg/ m <sup>2</sup> cyclophosphamide 600 mg/m <sup>2</sup> every 2 weeks for 4 cycles
	DCb	carboplatin (AUC 6) plus docetaxel (75 mg/ m <sup>2</sup> ) every 21 days for 6 cycles
TBCRC 030	Cis	cisplatin (75 mg/ m <sup>2</sup> every 3 weeks for 4 doses)
	P	paclitaxel 80 mg/ m <sup>2</sup> weekly for 12 cycles
TBCRC 031	Cis	cisplatin (75 mg/ m <sup>2</sup> every 3 weeks for 4 doses)
	AC	doxorubicin 60 mg/ m <sup>2</sup> ; cyclophosphamide 600 mg/ m <sup>2</sup> every 2-3 weeks for 4 doses
KEYNOTE 522	P+Cb+Pem→AC+Pem	Pembrolizumab (200 mg) every 3 weeks plus paclitaxel (80 mg/ m <sup>2</sup> weekly) plus carboplatin (AUC 5 every 3 weeks or 1.5 weekly) for 12 weeks; four cycles of pembrolizumab plus doxorubicin (60 mg/ m <sup>2</sup> ) or epirubicin (90 mg/ m <sup>2</sup> ) plus cyclophosphamide (600 mg/ m <sup>2</sup> every 3 weeks in 12 weeks)
	P+Cb→AC	Placebo (200 mg) every 3 weeks plus paclitaxel (80 mg/ m <sup>2</sup> weekly) plus carboplatin (AUC 5 every 3 weeks or 1.5 weekly) for 12 weeks; four cycles of placebo plus doxorubicin (60 mg/ m <sup>2</sup> ) or epirubicin (90 mg/ m <sup>2</sup> ) plus cyclophosphamide (600 mg/ m <sup>2</sup> every 3 weeks in 12 weeks)
NeoCart	EC→D	epirubicin 90 mg/ m <sup>2</sup> plus cyclophosphamide 600 mg/ m <sup>2</sup> four cycles, followed by docetaxel 100 mg/ m <sup>2</sup> for four cycles
	DCb	docetaxel (75 mg/ m <sup>2</sup> ) plus carboplatin (AUC 6) for six cycles
IMpassion031	nabP→AC	Nab-paclitaxel 125 mg/ m <sup>2</sup> weekly for 12 weeks, then four cycles plus doxorubicin (60 mg/ m <sup>2</sup> ) plus cyclophosphamide (600 mg/ m <sup>2</sup> every 2 weeks)
	nabP+Atezo→AC+Atezo	Nab-paclitaxel 125 mg/ m <sup>2</sup> weekly for 12 weeks, then four cycles plus doxorubicin (60 mg/ m <sup>2</sup> ) plus cyclophosphamide (600 mg/ m <sup>2</sup> every 2 weeks); atezolizumab 840 mg every 2 weeks